p16INK4a promoter methylation and protein expression in breast fibroadenoma and carcinoma
β Scribed by Angela Di Vinci; Luisa Perdelli; Barbara Banelli; Sandra Salvi; Ida Casciano; Ilaria Gelvi; Giorgio Allemanni; Edoardo Margallo; Beatrice Gatteschi; Massimo Romani
- Publisher
- John Wiley and Sons
- Year
- 2005
- Tongue
- French
- Weight
- 486 KB
- Volume
- 114
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
The potential role of p16^INK4a^ methylation in breast cancer is controversial whereas there are no data on fibroadenoma. To assess if inactivation of p16^INK4a^ by promoter hypermethylation occurs in this hyperproliferative benign breast lesion or, on the contrary, it is strictly related to the carcinogenic process, we have tested the different histological components of 15 cases of fibroadenoma and the intraductal and infiltrating components of 15 cases of carcinoma and their adjacent nonβtumoral epithelium. All samples were obtained by laserβassisted microdissection. The relationship between promoter methylation status, immunohistochemical protein expression and ki67 proliferative activity was evaluated for each lesion. Our data demonstrate that hypermethylation of p16^INK4a^ promoter is a common event occurring at similar frequency in all the different histological areas of the benign and malignant breast lesions taken into exam. Conversely, protein p16 expression, although heterogeneously distributed within the section, is considerably higher in breast carcinoma as compared to fibroadenoma in both tumoral and nonβtumoral epithelia and stroma. The protein localization was almost exclusively nuclear in fibroadenoma and nonβtumoral epithelia whereas, in carcinoma, the staining was both nuclear and cytoplasmic or cytoplasmic alone. Furthermore, in a subset of fibroadenoma with higher proliferative activity, p16 protein expression was substantially decreased as compared to those showing lower proliferation. We did not observe this association in carcinomas. Our data demonstrate that the hypermethylation of the p16^INK4a^ promoter is not specifically associated with malignancy and that, on the contrary, the overexpression of p16 and its cytoplasmic sequestration is a feature of breast carcinoma. Β© 2004 WileyβLiss, Inc.
π SIMILAR VOLUMES
## Background: It has been suggested that cyclin-dependent kinase inhibitors (cdkis), including p16 and p15, are tumor suppressor genes. alterations of cdkis have been found in most types of cancer. however, little is known about the status of p16 and p15 genes, including methylation of the promote
The p16 (CDKN2/MTS-1/INK4A) tumor-suppressor gene is frequently inactivated by DNA methylation in lung carcinomas. To clarify whether background anthracosis may play a role in DNA methylation and inactivation of the p16 gene, we examined DNA methylation of the p16-promoter region by methylation-spec
## Abstract Loss of p16^INK4a^ protein expression has frequently been related to DNA methylation in association with gene silencing. Although the methylation status of exon1Ξ± for p16^INK4a^ involvement in various cancers has been extensively analyzed, it has been pointed out that some inconsistenci
## BACKGROUND. Neuroendocrine neoplasms of the lung represent a wide spectrum of phenotypically and biologically distinct entities. Their histopathologic diagnosis, which carries therapeutic and prognostic significance, may sometimes be difficult because of their overlapping features. We previously